RECRUITING

Reduction of Anticholinergic Medications Among Persons With Schizophrenia or Other Psychiatric Disorders

Conditions

Schizophenia Disorder Schizoaffective Disorder Bipolar Disorder Psychiatric Disorders schizophrenia implementation study serious mental illness anticholinergic medication deprescription anticholinergic side effects Quality of life

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The goal of this study is to reduce Anticholinergic Medication (ACM) in persons with psychoses or serious mental illness, when these medications are no longer needed.

Official Title

Reduction of Anticholinergic Medications Project (RAMP) Among Persons With Schizophrenia or Other Psychiatric Disorders Across UPMC Behavioral Healthcare Partner Organizations Using a Stepped-wedge, Randomized Trial Study Design.

Quick Facts

Study Start:2025-07

Study Completion:2026-05

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT07043803

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:No

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
1. are 18 years or older 2. have a chart DSM V diagnosis of schizophrenia spectrum or schizoaffective or bipolar disorder or any other mental illness disorder 3. have received ACM and antipsychotic medications for 6 months or more 4. are considered to be clinically stable (by the patient's healthcare team) for 3 months or more 5. the ACM (e.g. benztropine and/or trihexyphenidyl) is being used to treat EPS associated with antipsychotic medications. 6. on an examination using the modified Simpson-Angus Extrapyramidal Symptoms Scale (head dropping and leg pendulousness items are dropped), no single item rated at 3 or 4. 7. able and willing to sign the approved informed consent document.	1. patients with ongoing Parkinsonian symptoms who require ACM meds for countering EPS side effects based on the Simpson-Angus Scale score cutoffs. 2. if the clinicians treating the potentially eligible patients consider them to be clinically unstable or if drug-addiction is the focus of treatment and participation in ACM de-prescription protocols is considered risky, the team will defer to the treating clinicians to exclude participants. 3. The same exclusions will apply to those persons undergoing medical procedures and treatments that make participation in this ACM deprescription trial unwise per the treating team.

Inclusion Criteria

Exclusion Criteria

1. are 18 years or older
2. have a chart DSM V diagnosis of schizophrenia spectrum or schizoaffective or bipolar disorder or any other mental illness disorder
3. have received ACM and antipsychotic medications for 6 months or more
4. are considered to be clinically stable (by the patient's healthcare team) for 3 months or more
5. the ACM (e.g. benztropine and/or trihexyphenidyl) is being used to treat EPS associated with antipsychotic medications.
6. on an examination using the modified Simpson-Angus Extrapyramidal Symptoms Scale (head dropping and leg pendulousness items are dropped), no single item rated at 3 or 4.
7. able and willing to sign the approved informed consent document.

1. patients with ongoing Parkinsonian symptoms who require ACM meds for countering EPS side effects based on the Simpson-Angus Scale score cutoffs.
2. if the clinicians treating the potentially eligible patients consider them to be clinically unstable or if drug-addiction is the focus of treatment and participation in ACM de-prescription protocols is considered risky, the team will defer to the treating clinicians to exclude participants.
3. The same exclusions will apply to those persons undergoing medical procedures and treatments that make participation in this ACM deprescription trial unwise per the treating team.

Contacts and Locations

Study Contact

Administrative Coordinator

CONTACT

4122465006

spinogattij@upmc.edu

Professor of Psychiatry, MD

CONTACT

412-246-5006

chengappakn@upmc.edu

Principal Investigator

Professor of Psychiatry, MD

PRINCIPAL_INVESTIGATOR

University of Pittsburgh

Study Locations (Sites)

Western Behavioral Health of the Alleghenies

Altoona, Pennsylvania, 16601

United States

UPMC Western Behavioral Health at Safe Harbor

Erie, Pennsylvania, 16508

United States

Western Behavioral Health Mon Yough

McKeesport, Pennsylvania, 16601

United States

Comprehensive Recovery Services (Pittsburgh) of Western Psychiatric Hospital, Ambulatory Clinics and Residential Programs - UPMC, Pittsburgh, PA

Pittsburgh, Pennsylvania, 15213

United States

Collaborators and Investigators

Sponsor: University of Pittsburgh

Professor of Psychiatry, MD, PRINCIPAL_INVESTIGATOR, University of Pittsburgh

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-07

Study Completion Date2026-05

Study Record Updates

Study Start Date2025-07

Study Completion Date2026-05

Terms related to this study

Keywords Provided by Researchers

schizophrenia
implementation study
serious mental illness
psychiatric disorders
anticholinergic medication deprescription
anticholinergic side effects
Quality of life

Additional Relevant MeSH Terms

Schizophenia Disorder
Schizoaffective Disorder
Bipolar Disorder
Psychiatric Disorders